Healthy Normotensives | Controlled hypertension | Hypertension with systolic BP 140–159 mmHg | Hypertension with systolic BP ≥ 160 mmHg | All withhypertension | ||
Group A | Group B | Group C | Group D | Groups B-D combined | ||
Group n | 852 | 206 | 501 | 148 | 855 | |
Mean ± SD or n (%)
|
Mean ± SD or n (%)
|
Mean ± SD or n (%)
|
Mean ± SD or n (%)
|
Mean ± SD or n (%)
|
ANOVA / χ2 test p-value | |
Women | 520 (61) | 115 (56) | 220 (44)*† | 70 (47)* | 405 (47) | <0.001 |
Men | 332 (39) | 91 (44) | 280 (56)*† | 78 (53)* | 449 (53) | |
Russian | 358 (42) | 144 (70)* | 280 (56)*† | 96 (65)* | 520 (61) | <0.001 |
Norwegian | 494 (58) | 62 (30)* | 221 (44)* | 52 (35)* | 335 (39) | |
Age (years) | 53±8 | 59±8* | 57±8* | 60±8*‡ | 58±8 | <0.001 |
BMI (kg/m2) | 26.0±4.4 | 29.3±5.2* | 28.9±5.2*† | 29.3±5* | 29.0±5.2 | <0.001 |
Systolic BP (mmHg) | 119±12 | 123±10* | 146±7*† | 171±11*†‡ | 145±18 | <0.001 |
Diastolic BP (mmHg) | 73±9 | 76±8* | 88±9*† | 97±10*†‡ | 87±11 | <0.001 |
LDL Cholesterol (mmol/l) | 3,7±0,9 | 3,7±1,0 | 3,7±1,0 | 3,7±0,9 | 3.7±9.3 | 0.400 |
HbA1C (%) | 5,6±0,7 | 5,6±0,5 | 5,7±0,8 | 5,6±0,7 | 5.6±0.7 | 0.466 |
Diabetes diagnosis (n) | 9 (1) | 35 (17)* | 25 (5)*† | 9 (6)*† | 69 (8) | <0.001 |
Smoking** (n) | 170 (20) | 23 (11)* | 95 (19) | 34 (23)† | 152 (18) | 0.018 |
Atrial fibrillation history (n) | 26 (3) | 10 (5) | 15 (3) | 7 (5) | 32 (4) | 0.242 |
Creatinin (mmol/l) | 78±15 | 84±18* | 81±30* | 82±16 | 82±25 | <0.001 |
Anti-hypertensive medication (n) | 0 | 206(100) | 175 (34) † | 75 (51)†‡ | 470 (53) | <0.001 |
RAS Drugs (n) | 0 | 159 (77) | 140 (28) † | 65 (44) †‡ | 15 (39) | <0.001 |
Diuretics (n) | 0 | 35 (17) | 40 (8) † | 16 (11) | 54 (8) | <0.001 |
Betablockers (n) | 0 | 68 (33) | 60 (12) † | 30 (20) † | 154 (18) | <0.001 |
Ca-Antagonists (n) | 0 | 33 (16) | 40 (8) † | 179 (11) | 86 (10) | 0.005 |
NT-proBNP (pmol/l) | 51 (30-89) | 74 (42–126) | 66 (32–123) | 78 (34–132) | 70 (36–127) | 0.180 |
NT-proBNP high | (0) | 16 (8)* | 55 (11)* | 16 (11)* | 87 (10)* | <0.001 |
BMI: body mass index; BP: blood pressure; LDL: low density lipoproteins; HDL: high density lipoproteins; LV EF: left ventricle ejection fraction; RAS: renin-angiotensin system; Ca: Calcium; HbA1C: glycosylated hemoglobin. NT-proBNP: median with quartiles. Antihypertensive medication was per definition absent in healthy controls and comparisons to this group were not made. **Refers to the active current smoking Bonferroni post-hoc analysis or χ2 test! * p<0.05 for difference towards group A † p<0.05 for difference towards group B ‡ p<0.05 for difference towards group C | BMI: body mass index; BP: blood pressure; LDL: low density lipoproteins; HDL: high density lipoproteins; LV EF: left ventricle ejection fraction; RAS: renin-angiotensin system; Ca: Calcium; HbA1C: glycosylated hemoglobin. NT-proBNP: median with quartiles. Antihypertensive medication was per definition absent in healthy controls and comparisons to this group were not made. **Refers to the active current smoking Bonferroni post-hoc analysis or χ2 test! * p<0.05 for difference towards group A † p<0.05 for difference towards group B ‡ p<0.05 for difference towards group C | BMI: body mass index; BP: blood pressure; LDL: low density lipoproteins; HDL: high density lipoproteins; LV EF: left ventricle ejection fraction; RAS: renin-angiotensin system; Ca: Calcium; HbA1C: glycosylated hemoglobin. NT-proBNP: median with quartiles. Antihypertensive medication was per definition absent in healthy controls and comparisons to this group were not made. **Refers to the active current smoking Bonferroni post-hoc analysis or χ2 test! * p<0.05 for difference towards group A † p<0.05 for difference towards group B ‡ p<0.05 for difference towards group C | BMI: body mass index; BP: blood pressure; LDL: low density lipoproteins; HDL: high density lipoproteins; LV EF: left ventricle ejection fraction; RAS: renin-angiotensin system; Ca: Calcium; HbA1C: glycosylated hemoglobin. NT-proBNP: median with quartiles. Antihypertensive medication was per definition absent in healthy controls and comparisons to this group were not made. **Refers to the active current smoking Bonferroni post-hoc analysis or χ2 test! * p<0.05 for difference towards group A † p<0.05 for difference towards group B ‡ p<0.05 for difference towards group C | BMI: body mass index; BP: blood pressure; LDL: low density lipoproteins; HDL: high density lipoproteins; LV EF: left ventricle ejection fraction; RAS: renin-angiotensin system; Ca: Calcium; HbA1C: glycosylated hemoglobin. NT-proBNP: median with quartiles. Antihypertensive medication was per definition absent in healthy controls and comparisons to this group were not made. **Refers to the active current smoking Bonferroni post-hoc analysis or χ2 test! * p<0.05 for difference towards group A † p<0.05 for difference towards group B ‡ p<0.05 for difference towards group C | BMI: body mass index; BP: blood pressure; LDL: low density lipoproteins; HDL: high density lipoproteins; LV EF: left ventricle ejection fraction; RAS: renin-angiotensin system; Ca: Calcium; HbA1C: glycosylated hemoglobin. NT-proBNP: median with quartiles. Antihypertensive medication was per definition absent in healthy controls and comparisons to this group were not made. **Refers to the active current smoking Bonferroni post-hoc analysis or χ2 test! * p<0.05 for difference towards group A † p<0.05 for difference towards group B ‡ p<0.05 for difference towards group C | BMI: body mass index; BP: blood pressure; LDL: low density lipoproteins; HDL: high density lipoproteins; LV EF: left ventricle ejection fraction; RAS: renin-angiotensin system; Ca: Calcium; HbA1C: glycosylated hemoglobin. NT-proBNP: median with quartiles. Antihypertensive medication was per definition absent in healthy controls and comparisons to this group were not made. **Refers to the active current smoking Bonferroni post-hoc analysis or χ2 test! * p<0.05 for difference towards group A † p<0.05 for difference towards group B ‡ p<0.05 for difference towards group C |